Tadalafil Tablet
Product Images NDC 82009-080

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 82009-080). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Quallent Pharmaceuticals Health Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

20mg (Tadalafil 20mg60)

Label for Tadalafil Tablets, USP 20 mg by Quallent Pharmaceuticals Health LLC. The label indicates 60 oral tablets with dosing instructions, storage guidelines, and manufacturer details. The label features the Quallent logo, NDC 82009-080-60, and an image of an oval tablet embossed with '20'.*

FDA Label Image

Figure1 (Tadalafil Fig1)

A forest plot chart depicting the mean difference in blood pressure changes (systolic and diastolic) comparing tadalafil 20 mg or 10 mg with placebo, coadministered with various drugs such as alcohol, alfuzosin, amlodipine, angiotensin II receptor blockers, doxazosin, tamsulosin, bendroflumethiazide, enalapril, and metoprolol. The x-axis shows the mean difference relative to placebo, with confidence intervals represented by horizontal error bars for each measurement.*

FDA Label Image

Figure2 (Tadalafil Fig2)

A forest plot chart showing fold change and 90% confidence intervals for various coadministered drugs interacting with Tadalafil. The x-axis represents change relative to Tadalafil alone, while the y-axis lists drugs including CYP3A inhibitors, CYP3A inducers, antacids, and H2 antagonists. Recommendations range from dose adjustment to avoid use or no dose adjustment.*

FDA Label Image

Figure3 (Tadalafil Fig3)

A scatter plot depicting fold changes and 90% confidence intervals in pharmacokinetic parameters (AUC, Cmax, and bleeding time) for various coadministered drugs with corresponding dose adjustment recommendations. The x-axis represents the change relative to the coadministered drug alone.*

FDA Label Image

Figure4 (Tadalafil Fig4)

A line graph depicting mean change from baseline in meters over 16 weeks, comparing placebo (N=82) and Tadalafil 40 mg (N=79). The graph shows the increase in distance for both groups over time with Tadalafil demonstrating a greater mean increase at weeks 4, 8, 12, and 16. Statistical significance is indicated by asterisks for Tadalafil versus placebo at multiple time points.*

FDA Label Image

Figure5 (Tadalafil Fig5)

A forest plot chart depicting placebo-adjusted mean change in 6-minute walk distance (meters) with 95% confidence intervals for Tadalafil 40 mg versus placebo. Subgroups displayed include all intent-to-treat subjects, Bosentan use, PAH etiology, baseline walk distance, gender, age, and baseline WHO functional class. Numerical values show change and confidence intervals for each group.*

FDA Label Image

Figure6 (Tadalafil Fig6)

A line graph depicting the percentage without clinical worsening over time in days for Tadalafil 40 mg, Tadalafil 20 mg, and placebo groups. The y-axis shows the percentage without clinical worsening from 0 to 100, and the x-axis represents time in days, up to 150 days. The graph compares the clinical outcomes of two Tadalafil doses versus placebo.*

FDA Label Image

Logo (Tadalafil Logo)

FDA Label Image

Tadalafil_structure (Tadalafil Structure)

Chemical structure of Tadalafil, shown as a line and ring diagram depicting its molecular composition.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.